z-logo
open-access-imgOpen Access
Efficacy and Determinants of Response to HER Kinase Inhibition inHER2-Mutant Metastatic Breast Cancer
Author(s) -
Lillian M. Smyth,
Sarina A. PihaPaul,
Helen Won,
Alison M. Schram,
Cristina Saura,
Sherene Loi,
Janice Lu,
Geoffrey I. Shapiro,
Dejan Juric,
Ingrid A. Mayer,
Carlos L. Arteaga,
Macarena I. de la Fuente,
Adam M. Brufksy,
Iben Spanggaard,
Morten MauSørensen,
Mónica Arnedos,
Víctor Moreno,
Valentina Boni,
Joohyuk Sohn,
Lee S. Schwartzberg,
Xavier González,
Andrés Cervantes,
FrançoisClément Bidard,
Alexander N. Gorelick,
Richard B. Lanman,
Rebecca J. Nagy,
Gary A. Ulaner,
Sarat Chandarlapaty,
Komal Jhaveri,
Elena I. Gavrila,
Catherine Zimel,
S. Duygu Selçuklu,
Myra Melcer,
Aliaksandra Samoila,
Yanyan Cai,
Maurizio Scaltriti,
Grace Mann,
Feng Xu,
Lisa D. Eli,
Melanie Dujka,
Alshad S. Lalani,
Richard Bryce,
José Baselga,
Barry S. Taylor,
David B. Solit,
Funda MericBernstam,
David M. Hyman
Publication year - 2019
Publication title -
cancer discovery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.795
H-Index - 163
eISSN - 2159-8290
pISSN - 2159-8274
DOI - 10.1158/2159-8290.cd-19-0966
Subject(s) - metastatic breast cancer , mutant , breast cancer , cancer research , kinase , cancer , oncology , biology , medicine , genetics , gene

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom